2 Corporate Drive
First Floor
South San Francisco, CA 94080
United States
650 239 2030
https://www.sentibio.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 48
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Dr. Timothy K. Lu M.D., Ph.D. | Co-founder, CEO, President & Director | 868.57k | N/D | 1981 |
Dr. Deborah A. Knobelman Ph.D. | CFO, Head of Corporate Development & Treasurer | 620.88k | N/D | 1974 |
Ms. Susan D. Berland | Senior Financial Executive & Independent Director | 57.5k | N/D | 1955 |
Dr. Kanya Rajangam M.D., Ph.D. | Head of Research & Development and Chief Medical Officer | 689.99k | N/D | 1974 |
Dr. Wilson Wong Ph.D. | Scientific Co-Founder & Member of Scientific Advisory Board | N/D | N/D | N/D |
Mr. Mike Rhee | Senior VP of Legal Affairs & Corporate Secretary | N/D | N/D | N/D |
Susan Kahlert | Controller | N/D | N/D | N/D |
Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
La calificación ISS Governance QuickScore de Senti Biosciences, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.